Joseph Lipscomb

Learn More
Expert panels are playing an increasingly important role in U.S. health policy decision making. A fundamental issue in these applications is how to synthesize the judgments of individual experts into a group judgment. In this paper we propose an approach to synthesis based on Bayesian hierarchical models, and apply it to the problem of determining physician(More)
OBJECTIVE The economic costs of hyperglycemia are substantial. Early detection would allow management to prevent or delay development of diabetes and diabetes-related complications. We investigated the economic justification for screening for pre-diabetes/diabetes. RESEARCH DESIGN AND METHODS We projected health system and societal costs over 3 years for(More)
Datasets characterized by highly non-Gaussian distributions pose interesting challenges for prediction and comparison goals. Health care expenditure data is a common example where point masses and severe skewness often complicate analyses. Parametric approaches can improve efficiency characteristics of estimators but may sacrifice robustness in the process.(More)
In 2004, an estimated 1.5 million persons in the United States will be diagnosed with cancer; about 560 000 will die from cancer; and more than 9.5 million will be undergoing curative treatment, coping with progressive disease, or living free of cancer after successful therapy (1). But many of these survivors still feel the aftershocks and downstream side(More)
OBJECTIVE Although screening for diabetes and prediabetes is recommended, it is not clear how best or whom to screen. We therefore compared the economics of screening according to baseline risk. RESEARCH DESIGN AND METHODS Five screening tests were performed in 1,573 adults without known diabetes--random plasma/capillary glucose, plasma/capillary glucose(More)
If the central business of cancer outcomes research is the pursuit of information relevant to a range of decision makers (1), the nature and scientific quality of the information currently being produced? How do we enhance the rigor and relevance of cancer outcomes research, with a concern not only for the meth-odological and empirical foundations but also(More)
BACKGROUND Since the 1970s, CHOP chemotherapy has been the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL). In 2002, randomized trials changed this standard by showing that adding rituximab immunotherapy to CHOP improved survival. However, how these results influenced chemoimmunotherapy adoption in clinical practice remains(More)
OBJECTIVE To develop an inventory of data sources for estimating health care costs in the United States and provide information to aid researchers in identifying appropriate data sources for their specific research questions. METHODS We identified data sources for estimating health care costs using 3 approaches: (1) a review of the 18 articles included in(More)
The Cancer Outcomes Measurement Working Group (COMWG) was a National Cancer Institute working group of 35 experts convened to examine the state of the science and identify future research priorities for outcomes assessment in cancer. The COMWG focused on three outcomes (health-related quality of life [HRQOL]), patient needs and satisfaction, and economic(More)